Arch Biopartners Inc's stock saw a slight increase today, but the overall performance over the last week reflects a notable decline.
Arch Biopartners Inc (ARCH.V) closed at C$0.93, marking a 1.10% increase on the day. However, the stock has seen a significant drop of 9.80% over the past week, highlighting a challenging period for the company. As a biotech firm focusing on innovative treatments, Arch Biopartners is navigating a complex landscape in the health care sector.
Advertisement
Arch Biopartners Inc
ARCH.V
ARCH.V
Arch Biopartners Inc
WealthAwesomeMarket cap
$62.50M
52W high
$1.66
52W low
$0.39
1W change
-9.80%
Beta
1.75
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ARCH's historical volatility
30-Day Vol
106.2%
Annualized
90-Day Vol
108.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$1.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.98 | C$0.68 – C$1.41 |
| 60 trading days | C$1.04 | C$0.62 – C$1.74 |
| 90 trading days | C$1.10 | C$0.58 – C$2.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the recent developments in Arch Biopartners' clinical trials and funding efforts while being mindful of the stock's volatility and recent performance trends.
Arch Biopartners Inc has a market cap of approximately C$62.5 million.
With a current profit margin and ROE of 0.0%, the company is still in the early stages of commercialization and is heavily reliant on successful trial outcomes to drive future growth.
Bull case
The recent approval to expand U.S. clinical sites for Arch Biopartners' Phase II trial could boost its growth potential and attract more investment.
Bear case
Despite the positive news about trial expansions, the stock's significant decline over the past month and low trading volume compared to the average may reflect investor skepticism.
Current Price Action
Advertisement
Arch Biopartners Inc's stock is currently trading at C$0.93, reflecting a 1.10% increase today. However, the stock has faced a downward trend over the past week, with a significant decline of 9.80%. Over the last month, the stock has decreased by 16.36%, and year-to-date, it is down 26.40%. The recent price action indicates a volatile market sentiment surrounding the company.
Recent Company News
Arch Biopartners has received central Institutional Review Board approval for its ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury. This approval allows the company to expand its clinical trial sites into the United States, following interest from clinicians at leading U.S. institutions. This development could potentially enhance the company’s visibility and growth prospects in the competitive biotech landscape.
Technical Picture
From a technical perspective, Arch Biopartners' stock is currently trading slightly below its 50-day moving average of C$0.95, indicating a bearish short-term trend. However, it is above its 200-day moving average of C$0.85, which suggests a more favorable long-term outlook. The stock's 52-week range is between C$0.39 and C$1.66, placing the current price at approximately 43% of this range. With a beta of 1.75, the stock exhibits higher volatility compared to the broader market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
